Payment overview · 2025
General Payments
$787.09
38 reported records · 9 companies
Healthcare provider profile · identity verified
James Ray Low Jr, MD
Allopathic & Osteopathic Physicians|Internal Medicine · JACKSONVILLE, TX · NPI 1083616403
Verified facts
What the public records show
CMS Open Payments records show James Ray Low Jr, MD received $787.09 in general payments during 2025 across 38 reported records.
HARMONY BIOSCIENCES LLC accounted for 29.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Rexulti, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 182 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 129 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $231.34 | 29.4% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $188.15 | 23.9% | 9 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $144.03 | 18.3% | 11 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $61.69 | 7.8% | 4 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $56.91 | 7.2% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $38.77 | 4.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $23.11 | 2.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $23.09 | 2.9% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.00 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $717.10 | 37 |
| Education | $69.99 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| WAKIX Normalized: wakix |
Drug | HARMONY BIOSCIENCES LLC | $161.35 | 5 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $144.03 | 11 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $116.49 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $81.69 | 5 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $71.66 | 4 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $56.91 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $38.77 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $23.11 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $23.09 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $20.36 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $18.41 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 163 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 182 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 129 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 94 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
182 | 24 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
129 | 26 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
19 | 14 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
94 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
129 | 26 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
106 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
163 | 26 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
25 | 24 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 484 | 91 |
| Losartan Potassium | Losartan Potassium | 450 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 433 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 403 | 78 |
| Simvastatin | Simvastatin | 362 | 79 |
| Metformin Hcl Er | Metformin Hcl | 312 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 306 | 69 |
| Gabapentin | Gabapentin | 280 | 49 |
| Alprazolam | Alprazolam | 267 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 252 | 53 |
| Potassium Chloride | Potassium Chloride | 227 | 58 |
| Duloxetine Hcl | Duloxetine Hcl | 211 | 33 |
| Metoprolol Succinate | Metoprolol Succinate | 205 | 45 |
| Meloxicam | Meloxicam | 204 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 43 |
| Tramadol Hcl | Tramadol Hcl | 192 | 40 |
| Farxiga | Dapagliflozin Propanediol | 182 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 180 | 47 |
| Carvedilol | Carvedilol | 179 | 28 |
| Escitalopram Oxalate | Escitalopram Oxalate | 172 | 31 |
| Omeprazole | Omeprazole | 166 | 39 |
| Eliquis | Apixaban | 163 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 158 | 21 |
| Glimepiride | Glimepiride | 152 | 28 |
| Ozempic | Semaglutide | 147 | 19 |
| Montelukast Sodium | Montelukast Sodium | 140 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 133 | 24 |
| Furosemide | Furosemide | 131 | 37 |
| Jardiance | Empagliflozin | 129 | 26 |
| Allopurinol | Allopurinol | 123 | 24 |
| Lisinopril | Lisinopril | 115 | 24 |
| Estradiol | Estradiol | 111 | 26 |
| Temazepam | Temazepam | 108 | 11 |
| Mounjaro | Tirzepatide | 106 | 16 |
| Ezetimibe | Ezetimibe | 105 | 25 |
| Lorazepam | Lorazepam | 103 | 14 |
| Finasteride | Finasteride | 102 | 22 |
| Ramipril | Ramipril | 101 | 20 |
| Pregabalin | Pregabalin | 100 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 99 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 94 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 94 | 18 |
| Cefuroxime | Cefuroxime Axetil | 83 | 70 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 81 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 80 | 19 |
| Nebivolol Hcl | Nebivolol Hcl | 78 | 13 |
| Azithromycin | Azithromycin | 76 | 66 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 75 | 14 |
| Prednisone | Prednisone | 73 | 22 |
| Irbesartan | Irbesartan | 72 | 13 |
| Spironolactone | Spironolactone | 71 | 13 |
| Donepezil Hcl | Donepezil Hcl | 68 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 64 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 63 | 14 |
| Mirtazapine | Mirtazapine | 63 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 61 | suppressed |
| Celecoxib | Celecoxib | 61 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 57 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 56 | 14 |
| Premarin | Estrogens, Conjugated | 54 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 51 | 15 |
| Dexlansoprazole Dr | Dexlansoprazole | 50 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 49 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 48 | suppressed |
| Synthroid | Levothyroxine Sodium | 46 | suppressed |
| Methylprednisolone | Methylprednisolone | 45 | 42 |
| Myrbetriq | Mirabegron | 45 | suppressed |
| Trulicity | Dulaglutide | 44 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 42 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 41 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 39 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 38 | 26 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 36 | 15 |
| Fluconazole | Fluconazole | 36 | 24 |
| Ropinirole Hcl | Ropinirole Hcl | 36 | suppressed |
| Linzess | Linaclotide | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 35 | suppressed |
| Digoxin | Digoxin | 34 | suppressed |
| Metformin Hcl | Metformin Hcl | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 27 |
| Promethazine Hcl | Promethazine Hcl | 33 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 33 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 32 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 31 | 30 |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 31 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Topiramate | Topiramate | 31 | suppressed |
| Atenolol | Atenolol | 30 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Bumetanide | Bumetanide | 28 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 27 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 27 | suppressed |
| Carbamazepine | Carbamazepine | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 25 | 24 |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 24 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 23 | suppressed |
| Hydrocortisone | Hydrocortisone | 23 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 23 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 22 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 22 | 14 |
| Colesevelam Hcl | Colesevelam Hcl | 22 | suppressed |
| Lansoprazole | Lansoprazole | 22 | suppressed |
| Olanzapine | Olanzapine | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Famotidine | Famotidine | 19 | suppressed |
| Klor-Con M20 | Potassium Chloride | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Rexulti | Brexpiprazole | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 14 |
| Valsartan | Valsartan | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 18 | suppressed |
| Sucralfate | Sucralfate | 18 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 18 | suppressed |
| Carisoprodol | Carisoprodol | 17 | suppressed |
| Carvedilol Er | Carvedilol Phosphate | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 17 | 17 |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Propafenone Hcl Er | Propafenone Hcl | 17 | suppressed |
| Testosterone | Testosterone | 17 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Budesonide Dr | Budesonide | 16 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 16 | 15 |
| Acebutolol Hcl | Acebutolol Hcl | 15 | suppressed |
| Cevimeline Hcl | Cevimeline Hcl | 15 | suppressed |
| Rabeprazole Sodium | Rabeprazole Sodium | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Moxifloxacin Hcl | Moxifloxacin Hcl | 14 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | suppressed |
| Risperidone | Risperidone | 14 | suppressed |
| Xifaxan | Rifaximin | 14 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Pramipexole Er | Pramipexole Di-Hcl | 13 | suppressed |
| Tadalafil | Tadalafil | 13 | suppressed |
| Telmisartan | Telmisartan | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Droxidopa | Droxidopa | 12 | suppressed |
| Nifedipine Er | Nifedipine | 12 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 12 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 12 | suppressed |
| Alclometasone Dipropionate | Alclometasone Dipropionate | 11 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $787.09 · 38 records | HARMONY BIOSCIENCES LLC | AIRSUPRA, ELIQUIS, FARXIGA, JARDIANCE, Kerendia, LEQVIO, NURTEC ODT, REXULTI, TRELEGY ELLIPTA, WAKIX, ZAVZPRET | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error